Legal & RegulatoryEvent: September 8, 2026
OpenOnco filed an extended form of three recommendations in an FDA docket for GRAIL's Galleri multi-cancer early detection test.
Published
Signal category
Legal & Regulatory
Quote
“I'm filing these three recommendations in an extended form to FDA docket FDA-2026-N-8004 today.”
— Alex Dickinson|OpenOnco team
Company
OpenOnco
Independent source of information on cancer liquid biopsy tests.
- Industry
- Medical and Diagnostic Laboratories
- Company size
- 1 employees
Liquid biopsy tests are reshaping cancer treatment by profiling cancers from a simple blood draw. The tests are advancing rapidly - resulting in complex choices for doctors and patients. OpenOnco is a non-profit effort to consolidate test information and provide navigation tools to help match the right test to the right patient.
Founded 2025